# Prevention of Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients

> **NCT06703593** · PHASE2 · COMPLETED · sponsor: **British University In Egypt** · enrollment: 80 (actual)

## Conditions studied

- Breast Cancer Female

## Interventions

- **DRUG:** Alpha lipoic acid

## Key facts

- **NCT ID:** NCT06703593
- **Lead sponsor:** British University In Egypt
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-01
- **Primary completion:** 2025-04-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2025-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06703593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06703593, "Prevention of Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06703593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*